Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Establishing the incidence and timing of hypoglycemia at a residential diabetes camp.

Mann EA, Lunos S, Carrel E, Omann T, Halper A, Kogler A, Miller BS, Sunni M, Bellin MD, Nathan BM.

Diabetes Res Clin Pract. 2019 May;151:146-151. doi: 10.1016/j.diabres.2019.04.003. Epub 2019 Apr 2.

PMID:
30951794
2.

Bone mineral density and body composition in children with congenital adrenal hyperplasia.

Halper A, Sanchez B, Hodges JS, Kelly AS, Dengel D, Nathan BM, Petryk A, Sarafoglou K.

Clin Endocrinol (Oxf). 2018 Jun;88(6):813-819. doi: 10.1111/cen.13580. Epub 2018 Mar 24.

3.

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.

Nathan BM, Boulware D, Geyer S, Atkinson MA, Colman P, Goland R, Russell W, Wentworth JM, Wilson DM, Evans-Molina C, Wherrett D, Skyler JS, Moran A, Sosenko JM; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31.

4.

Meal replacements followed by topiramate for the treatment of adolescent severe obesity: A pilot randomized controlled trial.

Fox CK, Kaizer AM, Rudser KD, Nathan BM, Gross AC, Sunni M, Jennifer Abuzzahab M, Schwartz BL, Kumar S, Petryk A, Billington CJ, Ryder JR, Kelly AS.

Obesity (Silver Spring). 2016 Dec;24(12):2553-2561. doi: 10.1002/oby.21633. Epub 2016 Nov 3.

5.

Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264-270.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Oct;39(10):e193-4. doi: 10.2337/dci16-0025. No abstract available.

6.

Accuracy of Continuous Glucose Monitoring in Patients After Total Pancreatectomy with Islet Autotransplantation.

Forlenza GP, Nathan BM, Moran A, Dunn TB, Beilman GJ, Pruett TL, Kovatchev BP, Bellin MD.

Diabetes Technol Ther. 2016 Aug;18(8):455-63. doi: 10.1089/dia.2015.0405. Epub 2016 Apr 22.

7.

Weight Loss Mediated Reduction in Xanthine Oxidase Activity and Uric Acid Clearance in Adolescents with Severe Obesity.

Tam HK, Kelly AS, Fox CK, Nathan BM, Johnson LA.

Child Obes. 2016 Aug;12(4):286-91. doi: 10.1089/chi.2015.0051. Epub 2016 Mar 15.

8.

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.

Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Apr;39(4):555-62. doi: 10.2337/dc15-1606. Epub 2016 Feb 16.

9.

Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.

Nathan BM, Rudser KD, Abuzzahab MJ, Fox CK, Coombes BJ, Bomberg EM, Kelly AS.

Clin Obes. 2016 Feb;6(1):73-8. doi: 10.1111/cob.12128. Epub 2015 Dec 18.

10.

Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.

Rickels MR, Ruedy KJ, Foster NC, Piché CA, Dulude H, Sherr JL, Tamborlane WV, Bethin KE, DiMeglio LA, Wadwa RP, Ahmann AJ, Haller MJ, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW; T1D Exchange Intranasal Glucagon Investigators.

Diabetes Care. 2016 Feb;39(2):264-70. doi: 10.2337/dc15-1498. Epub 2015 Dec 17.

11.

Successful Application of Closed-Loop Artificial Pancreas Therapy After Islet Autotransplantation.

Forlenza GP, Nathan BM, Moran AM, Dunn TB, Beilman GJ, Pruett TL, Bellin MD.

Am J Transplant. 2016 Feb;16(2):527-34. doi: 10.1111/ajt.13539. Epub 2015 Nov 20.

12.

Higher daily physical activity is associated with higher osteocalcin levels in adolescents.

Chahla SE, Frohnert BI, Thomas W, Kelly AS, Nathan BM, Polgreen LE.

Prev Med Rep. 2015;2:568-571.

13.

Prevalence of cardiovascular risk factors in youth with type 1 diabetes and elevated body mass index.

Redondo MJ, Foster NC, Libman IM, Mehta SN, Hathway JM, Bethin KE, Nathan BM, Ecker MA, Shah AC, DuBose SN, Tamborlane WV, Hoffman RP, Wong JC, Maahs DM, Beck RW, DiMeglio LA.

Acta Diabetol. 2016 Apr;53(2):271-7. doi: 10.1007/s00592-015-0785-1. Epub 2015 Jun 16.

PMID:
26077171
14.

Therapeutic inertia: underdiagnosed and undertreated hypertension in children participating in the T1D Exchange Clinic Registry.

Nambam B, DuBose SN, Nathan BM, Beck RW, Maahs DM, Wadwa RP, Tamborlane WV, Foster NC, Miller KM, Haller MJ; T1D Exchange Clinic Network.

Pediatr Diabetes. 2016 Feb;17(1):15-20. doi: 10.1111/pedi.12231. Epub 2014 Oct 21.

PMID:
25330905
15.

The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial.

Kelly AS, Rudser KD, Nathan BM, Fox CK, Metzig AM, Coombes BJ, Fitch AK, Bomberg EM, Abuzzahab MJ.

JAMA Pediatr. 2013 Apr;167(4):355-60. doi: 10.1001/jamapediatrics.2013.1045.

16.

Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults.

Polgreen LE, Jacobs DR Jr, Nathan BM, Steinberger J, Moran A, Sinaiko AR.

Obesity (Silver Spring). 2012 Nov;20(11):2194-201. doi: 10.1038/oby.2012.108. Epub 2012 Apr 30.

17.

Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study.

Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering MM, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ.

Obesity (Silver Spring). 2012 Feb;20(2):364-70. doi: 10.1038/oby.2011.337. Epub 2011 Nov 10.

18.

Postprandial endothelial function, inflammation, and oxidative stress in obese children and adolescents.

Metzig AM, Schwarzenberg SJ, Fox CK, Deering MM, Nathan BM, Kelly AS.

Obesity (Silver Spring). 2011 Jun;19(6):1279-83. doi: 10.1038/oby.2010.318. Epub 2011 Jan 13.

19.

Impaired fasting glucose in cystic fibrosis.

Frohnert BI, Ode KL, Moran A, Nathan BM, Laguna T, Holme B, Thomas W.

Diabetes Care. 2010 Dec;33(12):2660-4. doi: 10.2337/dc10-0613.

20.

Managing diabetes in cystic fibrosis.

Laguna TA, Nathan BM, Moran A.

Diabetes Obes Metab. 2010 Oct;12(10):858-64. doi: 10.1111/j.1463-1326.2010.01250.x. Review.

PMID:
20920037
21.

Recent trends in cystic fibrosis-related diabetes.

Nathan BM, Laguna T, Moran A.

Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):335-41. doi: 10.1097/MED.0b013e32833a780d. Review.

PMID:
20489612
22.

Identification and treatment of metabolic complications in pediatric obesity.

Ode KL, Frohnert BI, Nathan BM.

Rev Endocr Metab Disord. 2009 Sep;10(3):167-88. doi: 10.1007/s11154-009-9115-7. Review.

23.

The current state of pediatric obesity treatment.

Nathan BM.

Rev Endocr Metab Disord. 2009 Sep;10(3):163-5. doi: 10.1007/s11154-009-9114-8. No abstract available.

PMID:
19777354
24.

The use of hormonal therapy in pediatric heart disease.

Nathan BM, Sockalosky J, Nelson L, Lai S, Sergi C, Petryk A.

Front Biosci (Schol Ed). 2009 Jun 1;1:358-75. Review.

PMID:
19482707
25.

Metabolic complications of obesity in childhood and adolescence: more than just diabetes.

Nathan BM, Moran A.

Curr Opin Endocrinol Diabetes Obes. 2008 Feb;15(1):21-9. doi: 10.1097/MED.0b013e3282f43d19. Review.

PMID:
18185059
26.

The increase of type 2 diabetes mellitus in children.

Nathan BM.

Minn Med. 2007 Nov;90(11):39-43.

PMID:
18072472
27.

Impact of body mass index on growth in boys with delayed puberty.

Nathan BM, Sedlmeyer IL, Palmert MR.

J Pediatr Endocrinol Metab. 2006 Aug;19(8):971-7.

PMID:
16995581
28.

A quantitative trait locus on chromosome 6 regulates the onset of puberty in mice.

Nathan BM, Hodges CA, Supelak PJ, Burrage LC, Nadeau JH, Palmert MR.

Endocrinology. 2006 Nov;147(11):5132-8. Epub 2006 Jul 27.

PMID:
16873534
29.

The use of mouse chromosome substitution strains to investigate the genetic regulation of pubertal timing.

Nathan BM, Hodges CA, Palmert MR.

Mol Cell Endocrinol. 2006 Jul 25;254-255:103-8. Epub 2006 Jun 9. Review.

PMID:
16762493
30.

Regulation and disorders of pubertal timing.

Nathan BM, Palmert MR.

Endocrinol Metab Clin North Am. 2005 Sep;34(3):617-41, ix. Review.

PMID:
16085163
31.

Diabetic amyotrophy in an adolescent responsive to intravenous immunoglobulin.

Fernandes Filho JA, Nathan BM, Palmert MR, Katirji B.

Muscle Nerve. 2005 Dec;32(6):818-20.

PMID:
15991252

Supplemental Content

Loading ...
Support Center